Gerrit Draisma

Summary

Publications

  1. ncbi Gleason score, age and screening: modeling dedifferentiation in prostate cancer
    Gerrit Draisma
    Department of Public Health, Erasmus MC, Rotterdam, The Netherlands
    Int J Cancer 119:2366-71. 2006
  2. doi Digital mammography screening: weighing reduced mortality against increased overdiagnosis
    Rianne De Gelder
    Erasmus MC, Department of Public Health, P O Box 2040, 3000 CA, Rotterdam, The Netherlands
    Prev Med 53:134-40. 2011
  3. pmc Prostate-specific antigen screening in the United States vs in the European Randomized Study of Screening for Prostate Cancer-Rotterdam
    Elisabeth M Wever
    Department of Public Health, Erasmus Medical Center, PO Box 2040, 3000 CA Rotterdam, The Netherlands
    J Natl Cancer Inst 102:352-5. 2010
  4. pmc Interpreting overdiagnosis estimates in population-based mammography screening
    Rianne De Gelder
    Department of Public Health, Erasmus MC, Room AE 137, P O Box 2040, 3000 CA Rotterdam, The Netherlands
    Epidemiol Rev 33:111-21. 2011
  5. pmc Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context
    Gerrit Draisma
    Department of Public Health, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    J Natl Cancer Inst 101:374-83. 2009
  6. pmc Overdiagnosis and overtreatment of breast cancer: microsimulation modelling estimates based on observed screen and clinical data
    Harry J de Koning
    Erasmus MC, Department of Public Health, PO Box 1738, 3000 DR Rotterdam, The Netherlands
    Breast Cancer Res 8:202. 2006
  7. doi Breast cancer screening policies in developing countries: a cost-effectiveness analysis for India
    Quirine Lamberts Okonkwo
    Department of Public Health, Erasmus MC, University Medical Center Rotterdam, PO Box 2040, 3000 CA Rotterdam, The Netherlands
    J Natl Cancer Inst 100:1290-300. 2008
  8. doi Cost-effectiveness of opportunistic versus organised mammography screening in Switzerland
    Rianne De Gelder
    Erasmus MC, Department of Public Health, Rotterdam, The Netherlands
    Eur J Cancer 45:127-38. 2009
  9. doi How does early detection by screening affect disease progression? Modeling estimated benefits in prostate cancer screening
    Elisabeth M Wever
    Department of Public Health, Erasmus MC Rotterdam, The Netherlands
    Med Decis Making 31:550-8. 2011
  10. doi Breast cancer screening: evidence for false reassurance?
    Rianne De Gelder
    Department of Public Health, Erasmus MC, 3000 CA Rotterdam, The Netherlands
    Int J Cancer 123:680-6. 2008

Collaborators

Detail Information

Publications18

  1. ncbi Gleason score, age and screening: modeling dedifferentiation in prostate cancer
    Gerrit Draisma
    Department of Public Health, Erasmus MC, Rotterdam, The Netherlands
    Int J Cancer 119:2366-71. 2006
    ..Tumors dedifferentiate during the screen-detectable phase and consequently screening with PSA and early treatment can possibly prevent dedifferentiation...
  2. doi Digital mammography screening: weighing reduced mortality against increased overdiagnosis
    Rianne De Gelder
    Erasmus MC, Department of Public Health, P O Box 2040, 3000 CA, Rotterdam, The Netherlands
    Prev Med 53:134-40. 2011
    ..Digital mammography has been shown to increase the detection of ductal carcinoma in situ (DCIS) compared to screen-film mammography. The benefits and risks of such an increase were assessed...
  3. pmc Prostate-specific antigen screening in the United States vs in the European Randomized Study of Screening for Prostate Cancer-Rotterdam
    Elisabeth M Wever
    Department of Public Health, Erasmus Medical Center, PO Box 2040, 3000 CA Rotterdam, The Netherlands
    J Natl Cancer Inst 102:352-5. 2010
    ..26 in the United States vs 0.94 in ERSPC-Rotterdam. We conclude that the efficacy of PSA screening in detecting prostate cancer was lower in the United States than in ERSPC-Rotterdam...
  4. pmc Interpreting overdiagnosis estimates in population-based mammography screening
    Rianne De Gelder
    Department of Public Health, Erasmus MC, Room AE 137, P O Box 2040, 3000 CA Rotterdam, The Netherlands
    Epidemiol Rev 33:111-21. 2011
    ..Calculations based on earlier screening program phases may overestimate overdiagnosis by a factor 4. Sufficient follow-up and agreement regarding the chosen estimator are needed to obtain reliable estimates...
  5. pmc Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context
    Gerrit Draisma
    Department of Public Health, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    J Natl Cancer Inst 101:374-83. 2009
    ..Reported overdiagnosis estimates have also been variable, ranging from 25% to greater than 80% of screen-detected cancers...
  6. pmc Overdiagnosis and overtreatment of breast cancer: microsimulation modelling estimates based on observed screen and clinical data
    Harry J de Koning
    Erasmus MC, Department of Public Health, PO Box 1738, 3000 DR Rotterdam, The Netherlands
    Breast Cancer Res 8:202. 2006
    ..The increases in ductal carcinoma in situ (DCIS) are primarily due to mammography screening, but DCIS still remains a relatively small proportion of the total breast cancer problem...
  7. doi Breast cancer screening policies in developing countries: a cost-effectiveness analysis for India
    Quirine Lamberts Okonkwo
    Department of Public Health, Erasmus MC, University Medical Center Rotterdam, PO Box 2040, 3000 CA Rotterdam, The Netherlands
    J Natl Cancer Inst 100:1290-300. 2008
    ..Estimates and comparisons of the cost-effectiveness of feasible breast cancer screening policies in developing countries and identification of the determinants of cost and efficacy are needed...
  8. doi Cost-effectiveness of opportunistic versus organised mammography screening in Switzerland
    Rianne De Gelder
    Erasmus MC, Department of Public Health, Rotterdam, The Netherlands
    Eur J Cancer 45:127-38. 2009
    ..In this study, we compared the cost-effectiveness of both screening modalities in Switzerland...
  9. doi How does early detection by screening affect disease progression? Modeling estimated benefits in prostate cancer screening
    Elisabeth M Wever
    Department of Public Health, Erasmus MC Rotterdam, The Netherlands
    Med Decis Making 31:550-8. 2011
    ..Two commonly used screening-effect models are the stage-shift model, where mortality benefits are explained by the shift to more favorable stages, and the cure model, where early detection enhances the chances of cure from disease...
  10. doi Breast cancer screening: evidence for false reassurance?
    Rianne De Gelder
    Department of Public Health, Erasmus MC, 3000 CA Rotterdam, The Netherlands
    Int J Cancer 123:680-6. 2008
    ..0 days (95% C.I. 5.9-8.1) in symptomatic screened patients and 6.0 days (95% C.I. 4.0-8.0) in control patients. Our results show that false reassurance played, at most, only a minor role in breast cancer screening...
  11. ncbi Seventy-five years is an appropriate upper age limit for population-based mammography screening
    Jacques Fracheboud
    Department of Public Health, NETB, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
    Int J Cancer 118:2020-5. 2006
    ..At present, 75 years of age can be regarded as an appropriate upper age limit for the Dutch programme...
  12. doi Quality-of-life effects of prostate-specific antigen screening
    Eveline A M Heijnsdijk
    Department of Public Health, Erasmus Medical Center, P O Box 2040, 3000 CA Rotterdam, The Netherlands
    N Engl J Med 367:595-605. 2012
    ..However, the extent to which harms to quality of life resulting from overdiagnosis and treatment counterbalance this benefit is uncertain...
  13. pmc Race-specific impact of natural history, mammography screening, and adjuvant treatment on breast cancer mortality rates in the United States
    Nicolien T Van Ravesteyn
    Department of Public Health, Erasmus MC Room AE 134, P O Box 2040, 3000 CA Rotterdam, The Netherlands
    Cancer Epidemiol Biomarkers Prev 20:112-22. 2011
    ..The aim of this study is to investigate how much of the mortality disparity can be attributed to racial differences in natural history, uptake of mammography screening, and use of adjuvant therapy...
  14. ncbi Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer
    Gerrit Draisma
    Department of Public Health, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    J Natl Cancer Inst 95:868-78. 2003
    ..Both consequences have considerable impact on the net benefits of screening...
  15. ncbi Risk-based selection from the general population in a screening trial: selection criteria, recruitment and power for the Dutch-Belgian randomised lung cancer multi-slice CT screening trial (NELSON)
    Carola A Van Iersel
    Department of Public Health, Erasmus MC, Rotterdam, The Netherlands
    Int J Cancer 120:868-74. 2007
    ..When pooling with Danish trial data (n = +/-4,000) NELSON is the only trial without screening in controls that is expected to have 80% power to show a lung cancer mortality reduction of at least 25% 10 years after randomisation...
  16. ncbi Mammography benefit in the Canadian National Breast Screening Study-2: a model evaluation
    Adriana J Rijnsburger
    Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
    Int J Cancer 110:756-62. 2004
    ..6-34.1%. Enrolled women had above average risk. Screening sensitivity in both arms was high. A benefit of mammography screening is supported by our modeling of the CNBSS-2 results...
  17. ncbi Differences in natural history between breast cancers in BRCA1 and BRCA2 mutation carriers and effects of MRI screening-MRISC, MARIBS, and Canadian studies combined
    Eveline A M Heijnsdijk
    Department of Public Health, Erasmus MC, Rotterdam, The Netherlands
    Cancer Epidemiol Biomarkers Prev 21:1458-68. 2012
    ..Clinical observations suggest important differences in the natural history between breast cancers due to mutations in BRCA1 and BRCA2, potentially requiring different screening guidelines...
  18. pmc A note on the catch-up time method for estimating lead or sojourn time in prostate cancer screening
    Gerrit Draisma
    Department of Public Health, Erasmus MC, PO Box 2040 3000, CA Rotterdam, The Netherlands
    Stat Med 32:3332-41. 2013
    ..It is shown that this model is different from classic Markov-type models developed for breast cancer screening. In both models, the catch-up time method results in biased estimates of mean sojourn time...